Sorafenib
Form: Tablet
Strength: 200 mg
Reference Brands: Nexavar® (US & EU)
Category: Oncology Cancer Care
Sorafenib is a targeted therapy used in the treatment of advanced liver cancer (HCC), renal cell carcinoma (RCC), and thyroid cancer. As an oral kinase inhibitor, it works by blocking tumor cell proliferation and angiogenesis. Available under the brand name Nexavar®, it is marketed in 200 mg tablets in both the US and EU. Sorafenib is a critical component in the treatment of various solid tumors and is manufactured under GMP-compliant standards. Ideal for B2B pharmaceutical partners, it is supplied globally for oncology distributors and hospital tender markets seeking reliable oncology treatments.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View Details
Ifosfamide
Strength: 1 g/vial,2 g/vial, 3 g/vial
Form: Injection
Reference Brands: Ifex® (US), Holoxan® (EU)
View Details